Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy aims to treat prostate cancer with fewer side effects

NCT ID NCT05790213

Recruiting now Disease control Sponsor: University of Chicago Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing whether combining focal prostate ablation (a surgery that destroys only the cancerous part of the prostate) with a short course of hormone therapy can effectively treat intermediate-risk prostate cancer. The study will enroll 57 participants and measure how well the treatment controls cancer, as well as its impact on quality of life and side effects. The goal is to find a less invasive option that preserves healthy tissue and reduces long-term complications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Androgen deprivation therapy (hormone therapy) and focal prostate ablation (surgery to destroy part of the prostate)
What this could lead to
If successful, this combination could offer a less invasive treatment option for intermediate-risk prostate cancer, potentially reducing side effects compared to whole-gland treatments.
What could go wrong
This is a small, early-phase trial with only 57 participants, so results may not apply to everyone. The treatment may not fully eliminate the cancer, and side effects from hormone therapy or the procedure are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTERMEDIATE RISK PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

  • UChicago Medicine Comprehensive Cancer Center

    RECRUITING

    Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.